Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy
Jefferies Financial Group has upgraded Vor Biopharma (NASDAQ:VOR) to a "strong-buy" rating. The company, a clinical-stage biotech developing next-generation allogeneic stem cell therapies, has a consensus "Moderate Buy" rating from analysts with an average target price of $49.89. Vor Biopharma's stock opened at $14.70, with institutional investors owning approximately 97.29% of the shares.
https://www.marketbeat.com/instant-alerts/jefferies-financial-group-upgrades-vor-biopharma-nasdaqvor-to-strong-buy-2026-03-31/